Breaking new ground in heart failure management: novel therapies and future frontiers
Heart failure (HF) management is advancing in the field of cardiology, driven by the increasing availability of progressive medications. Emerging pharmacological therapies in heart failure management include SGLT-2 inhibitors, ARNI, Vericiguat, and Omecamtiv. Other novel therapies that are changing...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1643971/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233427846397952 |
|---|---|
| author | Arbab Khalid Paulette Rodriguez Vasiliki Tasouli-Drakou Abu-Bakr Ahmed Spencer Thatcher Jasmine K. Dugal Aditi Singh |
| author_facet | Arbab Khalid Paulette Rodriguez Vasiliki Tasouli-Drakou Abu-Bakr Ahmed Spencer Thatcher Jasmine K. Dugal Aditi Singh |
| author_sort | Arbab Khalid |
| collection | DOAJ |
| description | Heart failure (HF) management is advancing in the field of cardiology, driven by the increasing availability of progressive medications. Emerging pharmacological therapies in heart failure management include SGLT-2 inhibitors, ARNI, Vericiguat, and Omecamtiv. Other novel therapies that are changing the scope of HF management include IV Iron therapy and new antifibrotic agents, such as pirfenidone and pamrevlumab. With groundbreaking approaches such as gene and stem cell-based therapies, the possibilities include gene editing and RNA-based therapies. This article contrasts novel HF therapies against previously used therapies, highlighting their mechanism of action, clinical efficiency, and relevant clinical trials. Additionally, the limitations and challenges associated with the emerging therapies will be discussed. Overall, this literature review aims to provide a comprehensive understanding of how these therapies are transforming the management of HF and related cardiomyopathies. |
| format | Article |
| id | doaj-art-c71ab8269a9945d6b43f6aad187420a2 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-c71ab8269a9945d6b43f6aad187420a22025-08-20T05:32:57ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-08-011210.3389/fcvm.2025.16439711643971Breaking new ground in heart failure management: novel therapies and future frontiersArbab Khalid0Paulette Rodriguez1Vasiliki Tasouli-Drakou2Abu-Bakr Ahmed3Spencer Thatcher4Jasmine K. Dugal5Aditi Singh6Department of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesDepartment of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesDepartment of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesKirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesKirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesDepartment of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesDepartment of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United StatesHeart failure (HF) management is advancing in the field of cardiology, driven by the increasing availability of progressive medications. Emerging pharmacological therapies in heart failure management include SGLT-2 inhibitors, ARNI, Vericiguat, and Omecamtiv. Other novel therapies that are changing the scope of HF management include IV Iron therapy and new antifibrotic agents, such as pirfenidone and pamrevlumab. With groundbreaking approaches such as gene and stem cell-based therapies, the possibilities include gene editing and RNA-based therapies. This article contrasts novel HF therapies against previously used therapies, highlighting their mechanism of action, clinical efficiency, and relevant clinical trials. Additionally, the limitations and challenges associated with the emerging therapies will be discussed. Overall, this literature review aims to provide a comprehensive understanding of how these therapies are transforming the management of HF and related cardiomyopathies.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1643971/fullheart failurenovel therapiesSGLT-2 inhibitorsgene therapyantifibrotic agents pharmacologic advancementsARNI |
| spellingShingle | Arbab Khalid Paulette Rodriguez Vasiliki Tasouli-Drakou Abu-Bakr Ahmed Spencer Thatcher Jasmine K. Dugal Aditi Singh Breaking new ground in heart failure management: novel therapies and future frontiers Frontiers in Cardiovascular Medicine heart failure novel therapies SGLT-2 inhibitors gene therapy antifibrotic agents pharmacologic advancements ARNI |
| title | Breaking new ground in heart failure management: novel therapies and future frontiers |
| title_full | Breaking new ground in heart failure management: novel therapies and future frontiers |
| title_fullStr | Breaking new ground in heart failure management: novel therapies and future frontiers |
| title_full_unstemmed | Breaking new ground in heart failure management: novel therapies and future frontiers |
| title_short | Breaking new ground in heart failure management: novel therapies and future frontiers |
| title_sort | breaking new ground in heart failure management novel therapies and future frontiers |
| topic | heart failure novel therapies SGLT-2 inhibitors gene therapy antifibrotic agents pharmacologic advancements ARNI |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1643971/full |
| work_keys_str_mv | AT arbabkhalid breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT pauletterodriguez breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT vasilikitasoulidrakou breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT abubakrahmed breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT spencerthatcher breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT jasminekdugal breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers AT aditisingh breakingnewgroundinheartfailuremanagementnoveltherapiesandfuturefrontiers |